SCHEMBL10003466

SCHEMBL10003466

CCc1nc2c(cc1NC(=O)c1ccccc1)c(OCC(F)(F)F)c(C(=O)NC1CCS(O)(O)CC1)n2C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMO Q99835 1/20 0.45
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ LMNA P02545 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CTDSP1 Q9GZU7 1/20 0.35
▸ SCN9A Q15858 2/20 0.35
▸ AURKA O14965 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ SLC6A5 Q9Y345 1/20 0.34
▸ SCN1A P35498 1/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ CCR8 P51685 1/20 0.34
▸ PTK2 Q05397 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ CARM1 Q86X55 1/20 0.34
▸ PRMT6 Q96LA8 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003468 0.94 SMO (0.45) SMOCYP2D6CYP2C19LMNAGLA
SCHEMBL10003161 0.91 SMO (0.48) SMOCYP2D6CYP2C19SCN9ASCN1A
SCHEMBL10003160 0.91 SMO (0.48) SMOCYP2D6CYP2C19SCN9ASCN1A
SCHEMBL10003640 0.90 SMO (0.46) SMOCYP2D6CYP2C19SCN9AAURKA
SCHEMBL10003644 0.89 SMO (0.45) SMOCYP2D6CYP2C19LMNAGLA
SCHEMBL10003592 0.88 SMO (0.59) SMOCYP2D6CYP2C19LMNAGLA
SCHEMBL10003404 0.85 HTT (0.40) SMOCYP2D6CYP2C19LMNASCN9A
SCHEMBL12017140 0.84 CYP2D6 (0.37) SMOCYP2D6CYP2C19LMNAGLA
SCHEMBL10003336 0.82 SMN1; SMN2 (0.41) LMNAHSD17B10MEN1KMT2APOLB
SCHEMBL10003363 0.82 SMO (0.52) SMOCCR8MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH SMO 1/4885CYP2D6 1888/4885CYP2C19 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback